Tempus AI acquires Paige in an $81.25 million deal, adding FDA-cleared cancer detection tools and a dataset of 7 million ...

Tempus AI shares were higher after the company said it agreed to buy Paige, an AI company focused on digital pathology, for $81.3 million. The stock was up 8.4% at $83.17 and has more than doubled so ...

Tempus AI has acquired the digital pathology developer Paige, including its FDA-cleared, artificial intelligence-powered ...

In buying Paige, Tempus grows its dataset, expands its tech team and gains a foothold in digital pathology, the company said.

Tempus AI (NASDAQ:TEM) announced on Friday an acquisition of the AI company specializing in digital pathology, Paige, for $81 ...

Tempus AI shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 88.

Tempus AI achieves strong revenue growth and beats expectations, but ongoing losses and execution risks temper enthusiasm.

Tempus is acquiring Paige for $81.25 million, which is being paid predominantly in Tempus common stock, as well as Tempus' assumption of Paige's remaining commitment under its existing Microsoft Azure ...

It's called Recursion OS. Using 36 petabytes (36 million gigabytes) of biological and chemical data, Recursion OS can ...

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting ...

Tempus AI, Inc. (NASDAQ:TEM) investors will be delighted, with the company turning in some strong numbers with its latest results. Results overall were solid, with revenues arriving 5.7% better than ...

Tempus AI stock rose on the strength of Q2 sales momentum The company saw an adjusted loss of $0.22 per share on revenue of $314.6 million in the second quarter.